Wild carrot pentane-based fractions suppress proliferation of human HaCaT keratinocytes and protect against chemically-induced skin cancer by Mroueh, Mohamad A. et al.
RESEARCH ARTICLE Open Access
Wild carrot pentane-based fractions
suppress proliferation of human HaCaT
keratinocytes and protect against
chemically-induced skin cancer
Wassim N Shebaby1, Mohamad A Mroueh2, Petra Boukamp3,4, Robin I Taleb RI1, Kikki Bodman-Smith5,
Mirvat El-Sibai1 and Costantine F Daher1*
Abstract
Background: Previous studies in our laboratory showed that the Lebanese Daucus carota ssp. carota (wild carrot)
oil extract possesses in vitro and in vivo anticancer activities. The present study aims to examine the cytotoxic effect
of Daucus carota oil fractions on human epidermal keratinocytes and evaluate the chemopreventive activity of the
pentane diethyl ether fraction on DMBA/TPA induced skin carcinogenesis in mice.
Methods: Wild carrot oil extract was chromatographed to yield four fractions (F1, 100% pentane; F2, 50:50 pentane:
diethyl ether; F3, 100% diethyl ether; F4 93:7 chloroform:methanol). The cytotoxic effect of fractions (10, 25, 50 and
100 μg/mL) was tested on human epidermal keratinocytes (non-tumorigenic HaCaT cells and tumorigenic HaCaT-ras
variants) using WST a ssay. Cell cycle phase distribution of tumorigenic HaCaT-ras variants was determined by
flow cytometry post-treatment with F2 fraction. Apoptosis related proteins were also assessed using western blot.
The antitumor activity of F2 fraction was also evaluated using a DMBA/TPA induced skin carcinoma in Balb/c mice.
Results: All fractions exhibited significant cytotoxicity, with HaCaT cells being 2.4–3 times less sensitive than HaCaT-ras
A5 (benign tumorigenic), and HaCaT-ras II4 (malignant) cells. GC-MS analysis revealed the presence of a major compound
(around 60%) in the pentane/diethylether fraction (F2), identified as 2-himachalen-6-ol. Treatment of HaCaT-ras A5 and
HaCaT-ras II4 cells with F2 fraction resulted in the accumulation of cells in the sub-G1 apoptotic phase and decreased the
population of cells in the S and G2/M phases. Additionally, F2 fraction treatment caused an up-regulation of
the expression of pro-apoptotic (Bax) and down-regulation of the expression of anti-apoptotic (Bcl2) proteins.
A decrease in the phosphorylation of AKT and ERK was also observed. Intraperitoneal treatment with F2 fraction (50 or
200 mg/kg) in the DMBA/TPA skin carcinogenesis mouse model showed a significant inhibition of papilloma incidence
(mice with papilloma), yield (number of papilloma/mouse) and volume (tumor relative size) at weeks 15, 18 and 21.
Conclusion: The present data reveal that F2 fraction has a remarkable antitumor activity against DMBA/TPA-induced
skin carcinogenesis, an effect that may be mediated through inhibition of the MAPK/ERK and PI3K/AKT pathways.
Keywords: Daucus carota, Wild carrot, HaCaT, TPA/DMBA skin cancer
* Correspondence: cdaher@lau.edu.lb
1Department of Natural Sciences, School of Arts and Sciences, Lebanese
American University, P.O. Box 36, Byblos, Lebanon
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Shebaby et al. BMC Complementary and Alternative Medicine  (2017) 17:36 
DOI 10.1186/s12906-016-1531-0
Background
Skin cancer is one of the most common types of cancer
accounting for at least 40% of cases worldwide and is
even more common among Caucasians [1]. Carcinogen-
esis is a multistage process and it is characterized by
three stages including initiation, promotion and progres-
sion. Synthetic or natural agents, which may hinder, halt
or reverse the process of carcinogenesis at different
stages, would be considered an effective approach in
cancer prevention and treatment. Medicinal plants have
been reported to inhibit tumor formation in vivo by
blocking the initiation phase or slowing down the pro-
motion and progression phases of carcinogenesis [2–4].
Conventional chemotherapy or radiotherapy are often
accompanied with adverse side-effects. Therefore, there
is an increasing interest in pharmacological evaluation of
various natural products that possess anticancer and
chemopreventive properties with limited side effects [5].
Daucus carota (Linnaeus) ssp. carota, known as wild
carrot, is a member of the family Umbelliferae (Apiacae).
The plant grows in moderate regions throughout the
world [6] and is commonly consumed as a salad in the
Mediterranean diet or used as an additive in some recipes
[7]. In Lebanon, it is traditionally used for the treatment
of gastric ulcer, diabetes, muscle pain and cancer. The
plant has been also reported to exhibit antilithic, diuretic
[6, 8] antibacterial, and antifungal activities [9, 10]. Previ-
ous studies in our laboratory revealed that Daucus carota
oil extract (DCOE) possesses antioxidant [11], anti-
inflammatory and anti-ulcer activities [12]. It also exhib-
ited potent cytotoxicity against colon (Caco-2, HT-29),
breast (MCF-7, MDA-MB-23) [11] and human acute mye-
loid leukemia cells [13], as well as significant anti-tumor
promoting effect against DMBA/TPA skin carcinogenesis
in mice [4]. Recently, DCOE was subjected to chromato-
graphic separation and fractions were shown to possess
antioxidant, hepatoprotective [14] as well as anticancer ac-
tivity in vitro [14, 15]. The pentane/diethyl ether fraction
(F2) containing a major compound identified as 2-
himachalen-6-ol (61.4%), was found to suppress prolifera-
tion of HT-29 cells by inducing apoptosis [14]. It also
inhibited motility of MDA-MB231 and SF-268 cells and
reduced invasion of B16F-10 cells [15].
Keratinocytes are the most abundant cell type making
more than 95% of the skin cells. There are three main
types of skin cancer: melanoma, Basal cell carcinoma
(BCC) and squamous cell carcinoma (SCC). The most
common types of cancer in humans are the ones that
directly target keratinocytes and include basal cell car-
cinomas (BCC) and squamous cell carcinomas (SCC)
[16]. In contrast, melanoma is the least common, but
the most aggressive type of skin cancer and it is re-
sponsible for the majority of skin cancer mortalities.
Previous work in our laboratory revealed that DCOE
exhibited remarkable antitumor-promoting activity against
DMBA/TPA induced squamous cell carcinoma (papil-
loma) in mice. The first aim of this study, therefore, was
to evaluate the in vitro anti-proliferative effect of F2 frac-
tion in human skin carcinogenesis HaCaT model with its
three different stages of tumorigenicity (non-tumorigenic,
non-invasive and invasive). These cells are considered the
counterparts of the chemically induced squamous cell car-
cinoma in the DMBA/TPA skin carcinogenesis model in
mice. The second aim of this study was to further assess
the in vivo antitumor efficacy of F2 fraction in DMBA/
TPA skin carcinogenesis mouse model.
Methods
Chemicals and reagents
Dimethyl sulphoxide (DMSO), Dulbecco’s modified Eagle’s
medium (DMEM), Trypsin, 7,12-Dimethylbenz (a) an-
thracene (DMBA), 12-O-tetradecanoylphorbol-13-acetate
(TPA), were purchased from Sigma-Aldrich, St. Louis,
USA. WST-1 reagent was purchased from Roche,
Mannheim, Germany. Silica gel 60 was purchased
from ACROS organics, New Jersey, USA and Silica
gel 40 (35–70) mesh were purchased from Sigma Aldrich,
St. Louis, USA. All other chemicals used in the experi-
ments were of analytical grade.
Sample collection and oil extraction
Daucus carota (Linnaeus) ssp. carota mature umbels
(closed, yellow-brownish) were collected at the post
flowering season between July and August from Byblos,
Lebanon. The plant was identified according to the char-
acteristics described in the “Handbook of Medicinal
Herbs” [6] and confirmed by Dr. A. Houri, a Lebanese
plant expert at the Lebanese American University. A
voucher specimen of the plant material used in this
study has been deposited in the Department of Natural
Sciences herbarium. The extraction procedure was carried
out according to the method described by Zeinab et al.
[4]. Briefly, Daucus carota umbels were air dried in the
shade and then cut into small pieces for oil extraction in
methanol/acetone (1:1) for 72 h. The extract was then fil-
tered and evaporated to dryness under reduced pressure.
The residue was centrifuged and the oil was dried over an-
hydrous sodium sulfate. The final yield (3.47%) was stored
in a closed amber bottle at 4 °C until use.
DCOE fractionation
DCOE fractionation was carried out as described previ-
ously [14]. Briefly, thirty grams of DCOE were chroma-
tographed on a silica gel column (size 35–70 mesh),
eluted with pentane (100%), pentane: diethyl ether
(50:50), diethyl ether (100%) and chloroform: methanol
(93:7) to yield F1, F2, F3 and F4 fractions respectively.
Fractions were analyzed by TLC using hexane:ethyl
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acetate (70:30) as mobile phase and plates were stained
with 2% anisaldehyde. The chemical components of
various fractions were determined as previously de-
scribed [17].
Animals
All in vivo experiments were performed on male
adult BALB/c mice (6 weeks old) bred in the animal
facility of the Biology Department at the Lebanese
American University. Mice, weighing 18–21 g were
housed under optimum conditions of temperature set at
22 ± 2 °C, humidity at 50 ± 5% and an alternating cycle of
light and dark. The animals were supplied with standard
laboratory chow diet and water. All experimental proto-
cols were approved by the Department of Natural Sci-
ences Animal Ethical Committee, which complies with
the Guide for the Care and Use of Laboratory Animals
(Committee for the Update of the Guide for the Care and
Use of Laboratory Animals, 2010).
Cell lines and culture
The human HaCaT keratinocytes, HaCaT (non-tumori-
genic), HaCaT-ras A5 (benign tumorigenic) and HaCaT-
ras II4 (malignant) [18, 19] were cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with
10% heat-inactivated fetal bovine serum (FBS), 100 μg/
mL streptomycin and 100 U/mL penicillin. Cells were
maintained in a humidified atmosphere containing 5%
CO2 at 37 °C.
Cell proliferation assay
Proliferation of the HaCaT and HaCaT-ras variants was
tested using the WST-1 assay. Cells were plated in 96-
welled plates at a concentration of 5×104 cell/mL for
24 h. Afterwards, the three cell lines were treated with
increasing concentrations (10, 25, 50 and 100 μg/mL) of
DCOE fractions dissolved in DMSO for 48 h. Cell survival
was assessed using WST-1 reagent (Roche Applied Sci-
ence, Penzberg, Germany). The color intensity was quanti-
fied at 450 nm using Multiskan FC microplate ELISA
reader (Thermo fisher Scientific, Rockford, IL, USA).
Cell cycle analysis
The effect of F2 fraction on cell cycle distribution was
assessed by flow cytometry after staining of HaCaT-ras
A5, and HaCaT-ras II4 cells with propidium iodide (PI).
Briefly, both cells lines (1x105cells/mL) were treated with
different concentrations (25 and 50 μg/mL) of F2 frac-
tion and cultured in 6-well plates for 48 h. The treated
cells were harvested, washed with PBS and fixed with
70% ethanol on ice. The cells were then washed with
cold PBS, suspended in 200 μL 1× Propidium Iodide +
RNase staining solution and incubate at 37 °C in the
dark for 30 min. Propidium Iodide Flow Cytometry Kit
(Abcam, Cambridge, UK) was used for cell cycle analysis.
The DNA content of the cells was measured by C6 flow
cytometer (BD Accuri Cytometers, Ann Arbor, MI USA)
and the population of each phase was determined using
CFlow Plus analysis software (BD Accuri Cytometers, Ann
Arbor, USA).
Western blot
HaCaT-ras II4 cells were treated with two different con-
centrations of F2 (25 and 50 μg/mL) for 48 h. Adherent
and non-adherent cells were collected on ice, washed
twice with PBS, lysed with lysis buffer and centrifuged at
12,000 g for 10 min at 4 °C. The cell lysate was heated at
100 °C for 5 min, and the protein content was deter-
mined by the Bio-Rad protein assay (Bio-Rad, Hercules,
CA, USA).
Equal protein concentrations were subjected to Western
blot analysis as described previously [20]. The PVDF
membranes were blocked with blocking buffer (1× TBS,
0.1% Tween-20, 5% skim milk) for 2 h and then probed
with primary rabbit polyclonal antibodies to Caspase-3,
AKT, p-AKT, ERK and p-ERK (Abcam, Cambridge, UK)
and mouse monoclonal antibodies to actin, p53, p21,
Bcl-2, BAX (Santa Cruz, CA) at dilution ranging from
1/1000 – 1/5000 at 4 °C overnight. Later, the primary
antibodies were washed away with TBST for 2 h and
the membranes were treated with horseradish peroxidase
(HRP)-coupled secondary antibodies in blocking buffer at
a dilution of 1/5000 (Abcam, Cambridge, UK) for 1 h, and
washed with TBST afterwards. Finally, detection of each
protein was performed using the chemiluminescence ECL
kit (Abcam plc, Cambridge, UK). Blot images were ob-
tained with the image lab Software (BioRad, Chemidoc
imaging instrument).
Tumor promotion experiment
The dorsal surface of BALB/c mice was shaved using
electric clippers. Papillomas were initiated by a single
topical application of 190 nmol of 7,12-Dimethylbenz (a)
anthracene (DMBA) in 0.2 mL acetone. Three weeks
after initiation, the shaved area of the back of the mice
were treated by topically applying 8 nmol TPA in 0.2 mL
acetone twice weekly till the end of the experiment [21].
Before TPA promotion (30 min), three groups of 10
mice each received intraperitoneal injections of F2- frac-
tion (10 mg/kg, 50 mg/kg, 200 mg/kg) dissolved in
DMSO. Control group (n = 10) received an intraperito-
neal injections of DMSO. Papilloma development was
followed weekly for 21 weeks. Tumor incidence was
assessed as the percentage of mice in each group having
tumors on their back. The tumor volume was measured
at week 15, 17, 20. Tumor volume was estimated in
comparison to specific reference volume models. Briefly,
papillomas length and width were measured using a
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caliper and matched with similar clay tumor models of
known standardized volumes [16]. Papilloma smaller
than 1 mm in diameter were not counted. Mice in each
group were weighed at week 5, 13 and 21.
Statistical analysis
In vitro data were analyzed for statistical significance using
one way analysis of variance (ANOVA). Values of the dif-
ferent tested parameters within each group are presented
as mean ± SEM. Significant main effect differences were
tested using Bonferroni post hoc test for multiple compar-
isons. All data were analyzed with the statistical package
SPSS 18, and differences between groups were considered
statistically significant if p < 0.05. The IC50 was calculated
by a nonlinear regression curve with the use of Prism
Graph Pad Prism version 5.0 software for Windows. In
the in vivo study, statistical analysis was done using Linear
Mixed Effect Models in R (3.2.2) with the function lie
from the name package. Two models were built, one for
the number of papilloma and another for the papilloma
volume. In both models, the time and dosage were
considered as fixed effects while the mice id was con-
sidered as a random effect. Raw data are available in
a supporting Excel (Additional file 1) file presented
along with the manuscript.
Results
Effect of DCOE fractions on cell survival
The effects of the four fractions on cell survival were ex-
amined 48 h post-treatment. The data presented in
Figs. 1, 2 and 3 show that all three HaCaT variants ex-
hibited a dose-dependent decrease in cell survival. F1
and F2 demonstrated the strongest (p < 0.05) inhibitory
effect when compared with F3 and F4 fractions. Data
also revealed that the non-tumorigenic HaCaT cells were
almost 2.4–3 fold more resistant to cytotoxicity than the
two malignant variants (p < 0.05). The IC50 values of F1,
F2, F3 and F4 fractions for all three cell lines are pre-
sented in Table 1. In all tested cells, DMSO did not
show any significant effect on viability.
Effect of F2 fraction on cell cycle
Flow cytometric analysis was carried out to determine
the effect of F2 fraction on the cell cycle distribution.
Following a 48 h exposure to 25 μg/mL of F2, the frac-
tion of sub-G1 phase increased in HaCaT-ras II4 cells
from 2.24% (control) to 16.52% (Fig. 4). Similarly, the
fraction of cells in G1 phase increased from 42.15–
52.53%. Similarly, the number of HaCaT-ras A5 cells in
the sub-G1 phase increased significantly (p < 0.01) as
compared to DMSO control group (Fig. 5). This increase
coincided with considerably fewer cells in the S and G2/M
Fig. 1 Antiproliferative effect of DCOE fractions on HaCaTcells (non-tumorigenic). Cells were treated with F1-fraction (a), F2-fraction (b), F3-fraction (c),
F4-fraction (d) at different concentrations (10, 25, 50 and 100 μg/mL) or with 0.5% DMSO for 48 h followed by measurement of cell proliferation by
WST-1 assay. Data are expressed as % survival of cells. Data are the mean ± SEM from three independent experiments. * denotes P < 0.05 vs. DMSO
group as measured by one-way ANOVA
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Fig. 2 Antiproliferative effect of DCOE fractions on the HaCaT-ras A5 cells (benign tumorigenic). Cells were treated with F1-fraction (a), F2-fraction
(b), F3-fraction (c), F4-fraction (d) at different concentrations (10, 25, 50 and 100 μg/mL) or with 0.5% DMSO for 48 h followed by measurement of
cell proliferation by WST-1 assay. Data are expressed as % survival of cells. Data are the mean ± SEM from three independent experiments. * denotes
P < 0.05 vs. DMSO group as measured by one-way ANOVA
Fig. 3 Antiproliferative effect of DCOE fractions on the HaCaT-ras II4 cells (malignant). Cells were treated with F1-fraction (a), F2-fraction (b),
F3-fraction (c), F4-fraction (d) at different concentrations (10, 25, 50 and 100 μg/mL) or with 0.5% DMSO for 48 h followed by measurement of cell
proliferation by WST-1 assay. Data are expressed as % survival of cells. Data are the mean ± SEM from three independent experiments. * denotes
P < 0.05 vs. DMSO group as measured by one-way ANOVA
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phases (p < 0.05 and p < 0.01). Additionally, treatment
of both cell lines with 50 μg/mL of F2 significantly in-
creased the cell population in the sub-G1 to more than
96% with hypodiploid nuclei, indicating that F2 may
have caused DNA fragmentation which is a characteris-
tic of late apoptosis.
Effect of F2 fraction on the expression of apoptosis
related proteins in HaCat-II4 cells
To explore the mechanism by which F2 fraction induces
apoptosis, the expression levels of several pro-apoptotic
and anti-apoptotic proteins were examined by western
blot. Data shown in Fig. 6 revealed that treatment of
cells with F2 (25 and 50 μg/mL) caused a significant de-
crease in the level of caspase-3 (p < 0.05). While the level
of the anti-apoptotic protein Bcl-2 declined significantly
after treatment with the same doses of F2 (p < 0.05 and
p < 0.01 respectively), the level of pro-apoptotic protein
BAX was significantly increased (p < 0.05 and p < 0.01
respectively). Additionally, F2 treatment caused an in-
creased expression of p21 but it decreased that of p53.
Effect of F2 fraction on PI3K-AKT and MAP kinase pathways
in HaCat-II4 cells
The phosphatidylinositol 3-kinase (PI3K)-AKT and
MAP kinase signaling pathways are known to regulate
several cellular functions such as proliferation, and
apoptosis. Therefore, PI3K activation was measured
using Western blot analysis to look for the relative
expression of phosphorylated AKT (p-AKT) in relation to
non-phosphorylated AKT in HaCaT-ras II4 treated cell ly-
sates. On the other hand, the activity of the MAPK path-
way was assessed through examining the level of
phosphorylation of ERK. The results revealed that F2 frac-
tion caused a significant dose-dependent decrease in the
expression of p-AKT and p-ERK in comparison with the
DMSO-treated groups (Fig. 7).
Effect of the F2 fraction on tumor promotion in mice
The chemopreventive effect of F2 fraction (10, 50 or
200 mg/kg) was monitored for 21 weeks. The percentage
papilloma incidence (mice with papillomas) and the
average number of papillomas per mouse are available in
Additional file 2. Papilloma incidence in the control
(DMSO) group as well as in the treated groups was re-
corded as early as week 6 and increased rapidly to reach
100% at week 10 for the DMSO group. In all treated
groups, papilloma incidence reached 90% at week 13.
Tables 2, 3 and 4 show that the percentage of papilloma
incidence in the control group remained 100% at weeks
15, 18 and 21, whereas in the F2-treated groups (10, 50
and 200 mg/kg) papilloma incidence significantly de-
creased. Inhibition of papilloma incidence was maximal
at 200 mg/kg with 50% by the end of the experiment at
week 21 (Table 4).
Treatment with F2 (10, 50 and 200 mg/kg) not only
inhibited papilloma incidence but decreased also the
number of papillomas per mouse in a dose-dependent
manner (Additional file 2). At week 15, F2 inhibited pap-
illoma yield by 15, 17 and 38%, respectively (Table 2). At
week 18, the inhibition was 13, 20 and 35% (Table 3),
and at week 21 it reached 18, 28 and 42%, respectively
(Table 4). The linear mixed effect model of the number
of papilloma showed a significant interaction between
the time factor (weeks) and the dosage 50 mg and
200 mg. The coefficients of the interaction term between
the week and dosage is found to be −0.39 and −0.398 for
the dosage 50 mg and 200 mg respectively with values of
0.0049 and 0.0041 respectively. This clearly indicates
that the 50 mg and 200 mg treatment dosages have a
significant effect on decreasing the number of papilloma.
However, since both coefficients are almost identical a
50 mg/kg dosage seems to be optimal.
The effect of the F2 fraction on the volume of the papil-
lomas was also studied (Fig. 8). The linear mixed effect
model of the papilloma volume also showed a significant
interaction effect between the time factor and the treat-
ment dosage. All treatment dosages (10, 50 and 200 mg/
kg) were found to significantly lower the papilloma vol-
ume at weeks 15, 18 and 21with p-values < 0.05. As shown
in Table 5, the total volume of papillomas of control group
at week 15 was 83.5 mm3. Treatment of animals with F2
resulted in significant inhibition of papilloma volume by
28.5, 46.3 and 58.8%, respectively. Comparable results
were obtained at week 18 and at the end of the experi-
ment (week 21) (Table 5). The F2 treated animals did not
show significant changes in body weight during the study
period compared to the DMSO treated group (Fig. 9).
Discussion
DCOE have been proven lately to possess promising che-
mopreventive activity against DMBA/TPA-induced skin
carcinogenesis [4]. The present study was carried out to
evaluate the effects of DCOE fractions in vitro on different
tumorigenic HaCaT cells. Additionally, the fraction (F2)
Table 1 The IC50 (μg/ml) of DCOE fractions against different
human skin tumorigenic and non-tumorigenic cell lines
Fractions Cell line
HaCaT-ras A5 HaCaT-ras II4 HaCaT
F1 10.6 ± 0.58a,1 10.2 ± 0.90a,1 29.8 ± 0.58a,2
F2 14.6 ± 0.76b,2 11.4 ± 0.67a,1 33.2 ± 0.60b,3
F3 19.1 ± 0.98d,1 17.8 ± 0.62c,1 47.3 ± 0.75d,2
F4 16.2 ± 0.96c,1 14.5 ± 0.58b,1 43.4 ± 1.11c,2
Values are the mean ± SEM from three experiments. Values in a column not
sharing a common superscript letter are significantly different (p < 0.05) and
values in a row not sharing a common superscript number are significantly
different (p < 0.05)
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containing the major compound 2-himachalen-6-ol
(61.4%) was tested in vivo by using the DMBA/TPA
chemical carcinogenesis model. Treatment with the
different DCOE fractions caused a significant dose-
dependent decrease in viability in all treated cells, with F1
and F2 fractions being the most potent. Interestingly, the
Fig. 4 Effect of the F2 fraction on the cell cycle distribution of the HaCaT-rasII4 cells. a Cells were treated with either 25 or 50 μg/ml of F2 fraction
or with 0.5% DMSO for 48 h, after which cells were stained with PI and analyzed for DNA content by flow cytometry. The sub-G1 peak is
considered as the apoptotic portion. The results shown are representative of three independent experiments. b Bar graphs showing the
percentages of cell population of each phase of the cell cycle. Data are means ± SEM of three independent experiments. * denotes P< 0.05 and ** denotes
P< 0.01 vs. DMSO group as measured by one-way ANOVA
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obtained results revealed a cytotoxic selectivity of the
fractions (2.4 – 3 folds) against the tumorigenic vari-
ants, as compared to the non-tumorigenic HaCaT cells.
Similar to previous studies with human breast [4, 20]
and colon cancer (HT-29 Caco-2) cells [14], the F1 and
F2 fractions were found to be the most potent ones.
The major sesquiterpenes present in F1, the α-
humulene and β-caryophyllene, have been reported to
be active against various types of human cancer cells
[22–24]. On the other hand, the cytotoxicity of the F2
fraction could be primarily due to the presence of the
major sesquiterpene 2-himachalene-6-ol which constitutes
Fig. 5 Effect of the F2 fraction on the cell cycle distribution of the HaCaT-rasA5 cells. a Cells were treated with either 25 or 50 μg/ml of F2 fraction
or with 0.5% DMSO for 48 h, after which cells were stained with PI and analyzed for DNA content by flow cytometry. The sub-G1 peak is considered
as the apoptotic portion. The results shown are representative of three independent experiments. b Bar graphs showing the percentages
of cell population of each phase of the cell cycle. Data are means ± SEM of three independent experiments. * denotes P < 0.05 and ** denotes P < 0.01
vs. DMSO group as measured by one-way ANOVA
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Fig. 6 Western blot analysis of apoptosis related proteins in HaCaTras II4 cells. a Effect of the F2 fraction on the expression level of p21, p53,
caspase-3, Bcl-2 and Bcl-2-associated X (BAX) proteins. Expression of β-actin was used as an internal control. Cells were treated with 25
and 50 μg/ml of F2-fraction or with 0.5% DMSO for 48 h. Western blots are representative of three independent experiments. b The
densitometer-intensity data of the proteins of each blot is presented as mean ± SEM from three independent experiments. * denotes P < 0.05 and
** denotes P < 0.01 vs. DMSO as measured by one-way ANOVA
Fig. 7 Western blot analysis of the PI3K/Akt and MAPK/ERK? pathways in HaCaT-ras -II4 cells. a Effect of the F2 fraction on the expression level of
AKT, p-AKT, ERK, p-ERK proteins. Cells were treated with 25 and 50 μg/ml of F2-fraction and cells treated with 0.5% DMSO for 48 h. Western blots
were representative of three independent experiments. b The densitometer-intensity data of the proteins of each blot is presented as mean ±
SEM from three independent experiments. * denotes P < 0.05 and ** denotes P < 0.01 vs. DMSO as measured by one-way ANOVA
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61.4%. Flow cytometry analysis on HaCaT-ras II4 and
HaCaT-ras A5 cells clearly indicated that F2 treat-
ment induced accumulation of cells in the sub-G1
apoptotic phase and decreases the fraction of cells be-
ing in S and G2/M phases. Together this suggests in-
duction of apoptosis and cell cycle arrest by F2.
Similar results were obtained on human colon and
breast cancer cells after treatment with both F1 and
F2 fractions [14, 20]. To explore the possible mecha-
nisms leading to apoptosis induced by F2 treatment,
several components of the apoptotic pathways were
examined. The present data reveal that treatment of
HaCaT-ras II4 cells with F2 caused an up-regulation
of the pro-apoptotic Bax and a decrease in the anti-
apoptotic protein Bcl-2, resulting in a lower Bcl2/Bax
ratio which favors apoptotic cell death. The anti-
apoptotic protein, Bcl-2, has been shown to form a
complex with Bax protein, thereby preventing its pro-
apoptotic activity [25]. Bcl2 protein is known to in-
hibit apoptosis by preventing Bax translocation to
mitochondrial membrane and subsequent release of
cytochrome c [26, 27]. The present results also showed
that treatment of HaCaT-ras II4 cells with F2 fraction in-
duced a decrease in the level of the inactive caspase-3 in-
dicating its potential cleavage into the activated form.
Once activated, the executioner caspase-3 causes the
proteolytic cleavage and activation of a wide variety
of downstream protein targets [28]. Accordingly, these
results suggest that the induction of apoptosis might
be mediated via the mitochondrial pathway.
The induction of cell apoptosis by p53 and p21
(WAF1, Cip-1) is well documented [29]. Although p21 is
a direct p53 target, it is also known to be regulated by
several other tumor suppressors [30]. The current re-
sults show that F2 causes an increase in the expression
of p21 with a decrease in p53 levels in HaCaT-ras II4
cells. Such observation suggests that the cell cycle arrest
and apoptosis in HaCaT-ras II4 cells is mediated through
the up-regulation of the expression of p21 in a p53-
independent manner. The altered response in p53 ex-
pression may be attributed to the presence of mutant
p53 in these cells since previous studies conducted in
our laboratory have shown that F2 fraction caused p53
up-regulation in HT-29 colon cancer cells [14]. The
present findings are in accordance with previous reports
indicating that polyphenols such as curcumin [31], and
other wine polyphenols including caffeic acid, resveratrol
and quercetin [32] down-regulate p53 in cancer cells
harboring mutant p53 gene.
Cellular signaling pathways such as the MAPK path-
way and PI3K pathway which are involved in control-
ling cell cycle, cell proliferation and apoptosis are
routinely found to be upregulated in cancer cells [33,
34]. ERK1/2 (MAPK) is a transcription factor that leads
to the expression of several gene products which posi-
tively regulate cell survival [35]. It was reported that
Table 2 The inhibitory effects of different concentrations of F2-fraction on the promotion of mouse skin papilloma at week 15 in
tumor-bearing mice
Papilloma Yield Papilloma Incidence
Treatments % Survival Weeks of 1st PAPS PAPS/Mouse % Inhibition % Mice with PAPS % Inhibition
Control (DMSO) 100 6 14.7 ± 0.55 0 100 0
10 mg/Kg 100 6 12.5 ± 0.34* 15 90 10
50 mg/Kg 100 7 12.2 ± 0.33* 17 80 20
200 mg/Kg 100 7 9.1 ± 0.46* 38 80 20
Values are mean ± SEM. n = 10
*P < 0.05
Table 3 The inhibitory effects of different concentrations of F2-fraction on the promotion of mouse skin papillomaat week 18 in
tumor-bearing mice.
Papilloma Yield Papilloma Incidence
Treatments % Survival Weeks of 1st PAPS PAPS/Mouse % Inhibition % Mice with PAPS % Inhibition
Control (DMSO) 100 6 13.6 ± 0.30 0 100 0
10 mg/Kg 100 6 11.9 ± 0.32* 13 80 20
50 mg/Kg 100 7 10.9 ± 0.35** 20 60 40
200 mg/Kg 100 7 8.8 ± 0.44** 35 60 40
Values are mean ± SEM. n = 10
*P < 0.05, **P < 0.001 vs control
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constitutively activated ERK is responsible for the in-
creased cell growth in various cancers [35, 36]. Further-
more, activation of ERK 1/2 has also been shown to
prevent apoptosis in response to various types of stim-
uli such as tumor necrosis factor and radiation [37].
Whereas, down-regulation of ERK activity is known
to be associated with apoptosis [38]. In the current
study, treatment of HaCaT-ras II4 cells with F2 frac-
tion significantly inhibited the phosphorylation of
ERK. This down regulation of activation was associ-
ated with a decrease in cell survival and proliferation.
We speculate that the induction of apoptosis by F2
may be mediated partly through the inhibition of the
MAPK/ERK pathway. The AKT protein, main down-
stream effector of PI3K, is a key mediator of cell sur-
vival [39]. AKT activity has been reported previously
to be increased in various cancers, including melan-
oma, colon, brain, breast and prostate [33, 40, 41].
Additionally, the PI3K/AKT survival pathway inhibits
apoptosis and promotes tumor cell survival through
different types of stimuli such as growth factor with-
drawal and loss of cell adhesion [42]. The present
data revealed that F2 fraction caused a considerable
reduction in AKT phosphorylation in the HaCaT-ras
II4 cells, reflecting an inhibition of the PI3K/AKT
pathway.
The chemopreventive effect of the F2 fraction was
evaluated in DMBA/TPA-induced mouse skin carcino-
genesis. The results demonstrate that intraperitoneal
injection of F2 fraction at the promotion stage caused a
significant reduction in papilloma incidence, yield and
volume. These results are consistent with previous
work conducted in our laboratory using unfractionated
DCOE [4]. In addition, F2 fraction was shown to mark-
edly increase the level of glutathione S-transferase
(GST) in CCl4-treated mice [17], an enzyme involved
in the detoxification of carcinogens and in turn protect
cellular components against toxic compounds and
chemical carcinogenesis [43]. Therefore, the chemopre-
ventive action of F2 against DMBA/TPA-induced skin
Table 4 The inhibitory effects of different concentrations of F2-fraction on the promotion of mouse skin papillomaat week 21 in
tumor-bearing mice.
Papilloma Yield Papilloma Incidence
Treatments % Survival Weeks of 1st PAPS PAPS/Mouse % Inhibition % Mice with PAPS % Inhibition
Control (DMSO) 100 6 13.3 ± 0.29 0 100 0
10 mg/Kg 100 6 10.9 ± 0.52* 18 80 20
50 mg/Kg 100 7 9.6 ± 0.50** 28 60 40
200 mg/Kg 100 7 7.7 ± 0.71** 42 50 50
Values are mean ± SEM. n = 10
*P < 0.05, **P < 0.001 vs control
Fig. 8 Effect of F2 treatment on the papilloma volume in tumor-bearing mice. Average variations in papilloma volume (mm3) of all groups (10,
50 and 200 mg/kg) was measured at weeks 15, 18 and 21 in tumor bearing-mice. Bars represent mean papilloma volume ± SEM. * denotes P < 0.05
and ** denotes P < 0.01 compared with control (DMSO) mice as measured by one-way ANOVA
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carcinogenesis may be partly attributed to this en-
hanced activity of GST. Earlier studies in our labs have
shown that DCOE percentage yield was 3.47% and con-
tained a major compound constituting around 30% of
the crude oil content [4]. In the present study, F2 frac-
tion was shown to be the most active of DCOE frac-
tions and contained around 60% of that major
compound. Assuming that it is the major biologically
active compound of DCOE, then a 70 kg adult consum-
ing 67 g of the edible umbel would achieve the dose of
10 mg/kg body weight of this compound. The con-
sumption of the whole umbel would provide the con-
sumer with additional anticancer compounds present in
F1 fraction and to a lesser extent in F3 and F4 fractions.
Since F1 and F2 fraction are the most potent fractions
and not water soluble, it is recommended for maximal
benefit to consume the whole umbel rather than by in-
fusion form. In the present study, the animals were
treated for 21 weeks with doses of 10–200 mg/kg body
weight without incidence of death, thus indicating high
safety of the F2 fraction. In comparison with a com-
monly used chemotherapeutic drug, cisplatin, the low-
est dose used in the current study is about three times
higher. Knowing that it is still a fraction, chromato-
graphic purification of the F2 would most likely lead to
the use of a lower and comparable dose to cisplatin.
Conclusions
The current study demonstrates that Daucus carota
pentane-diethyl ether fraction (F2) displays an enhanced
selective cytotoxicity against the tumorigenic HaCaT-ras
variants as compared to non-tumorigenic human HaCaT
skin keratinocytes by inducing caspase-dependent apop-
totic cell death. The F2-induced cytotoxicity is mainly me-
diated through inhibition of the MAPK/ERK and PI3K/
AKT pathways. The anticancer activity of F2 was also con-
firmed in vivo using the DMBA/TPA skin carcinogenesis
model. Further studies will now be conducted to isolate,
chemically characterize and pharmacologically evaluate
the main constituents of this F2 fraction.
Table 5 The inhibitory effects of different concentrations of F2 fraction on the volume of papilloma (mm3) at weeks 15, 18 and 21
in tumor-bearing mice
Week 15 Week 18 Week 21
Treatments Tumor Volume % Inhibition Tumor Volume % Inhibition Tumor Volume % Inhibition
Control (DMSO) 83.5 ± 6.0 0 105.3 ± 5.0 0 133.3 ± 6.8 0
10 mg/Kg 59.7 ± 5.3* 28.5 85.5 ± 4.2* 18.8 116.0 ± 3.6* 13.0
50 mg/Kg 44.8 ± 5.7** 46.3 60.6 ± 2.8** 42.5 82.9 ± 3.8** 37.8
200 mg/Kg 34.4 ± 4.2** 58.8 40.0 ± 2.7** 62.0 61.2 ± 3.0** 54.0
Values are mean ± SEM. n = 10
*P < 0.05, **P < 0.001 vs control
Fig. 9 Effect of F2 treatment on the body weight of mice. Average variations in the body weight of the mice of all groups (DMSO, 10, 50,
200 mg/Kg) measured at weeks 5, 13 and 21. Bars represent mean of body weight ± SEM from groups of 10 mice
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